Rosuvastatin + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Aortic Stenosis
Conditions
Aortic Stenosis
Trial Timeline
Nov 1, 2002 → Sep 1, 2008
NCT ID
NCT00800800About Rosuvastatin + Placebo
Rosuvastatin + Placebo is a phase 3 stage product being developed by AstraZeneca for Aortic Stenosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00800800. Target conditions include Aortic Stenosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02546323 | Phase 3 | Completed |
| NCT00929734 | Phase 2 | Completed |
| NCT00951132 | Phase 2 | Withdrawn |
| NCT00990028 | Phase 1/2 | Completed |
| NCT00783042 | Phase 1 | Completed |
| NCT00673582 | Approved | Terminated |
| NCT00689416 | Phase 1 | Completed |
| NCT00329758 | Phase 2 | Completed |
| NCT00355615 | Phase 3 | Completed |
| NCT00658463 | Approved | Completed |
| NCT00800800 | Phase 3 | Completed |
Competing Products
20 competing products in Aortic Stenosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban 5 MG + Apixaban 2.5 MG + Warfarin | Artivion | Phase 3 | 72 |
| Edoxaban | Daiichi Sankyo | Phase 3 | 77 |
| NOAC + DAPT | Daiichi Sankyo | Approved | 85 |
| Ticagrelor + Placebo | AstraZeneca | Phase 2 | 52 |
| candesartan + placebo | AstraZeneca | Phase 3 | 77 |
| Sugammadex | Merck | Approved | 85 |
| bisoprolol + placebo | Merck | Approved | 85 |
| Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet | Merck | Phase 2/3 | 65 |
| Pelacarsen (TQJ230) 80mg + Matching placebo | Novartis | Phase 2 | 52 |
| fluvastatin | Novartis | Phase 2 | 52 |
| ACZ885 + Placebo | Novartis | Phase 2 | 52 |
| Evolocumab + Placebo | Amgen | Phase 1 | 32 |
| atorvastatin (Lipitor) | Pfizer | Approved | 84 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 76 |
| Ataciguat + Placebo | Sanofi | Phase 1 | 32 |
| Ataciguat (HMR1766) | Sanofi | Phase 2 | 51 |
| Haemocomplettan® P + Saline solution | CSL | Phase 2 | 51 |
| Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) | Bayer | Phase 3 | 74 |
| Acetylsalicylic acid + Clopidogrel + Rivaroxaban | Bayer | Phase 3 | 74 |
| Desflurane | Baxter | Approved | 82 |